Backgrounds: Non-Hodgkin's lymphoma and Hodgkin's lymphomas (HL) are lymphoid neoplasms. Hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) are viruses that could proliferate in lymphoid tissues. These viruses may cause lymphoproliferative diseases. The aim of this study was to evaluate the seroprevalence of HBV, HCV, and HIV in patients with diffuse large B-cell lymphoma (DLBCL) and HL, to compare the relationship between these two disease groups and to determine the relationship between the three viruses and their characteristics. Materials and Methods: The study was a retrospective study. Patients who were followed up in hematology and hepatitis outpatient units between January 01, 2012, and May 01, 2019, were included in the study. Results: A statistically significant relationship was observed between the disease groups in terms of hepatitis B surface antigen (HBsAg), hepatitis B core (HBc) IgG antibody, hepatitis B e antigen (HBeAg), and anti-HBe seropositivities (P = 0.004, P = 0.006, P = 0.041, and P = 0.014, respectively). There was also a statistically significant relationship between the disease groups in terms of anti-HCV seropositivity (P = 0.029). HBsAg, anti-HBc IgG, HBeAg, anti-Hbe, and HCV seropositivity rates were higher in patients with DLBCL than in patients with HL. Conclusion: These findings suggest that there may be a relationship between hepatitis viruses and DLBCL. Evaluation of HBV and HCV infections in these patients before starting treatment is thought to be beneficial in initiating antiviral prophylaxis to prevent reactivation in seropositive cases. In addition, care should be taken for the development of lymphoma in the follow-up of HCV and HBV infections.


中文翻译：

---

弥漫性大 B 细胞淋巴瘤和霍奇金淋巴瘤患者乙型肝炎病毒、丙型肝炎病毒和人类免疫缺陷病毒血清阳性率的评估


背景：非霍奇金淋巴瘤和霍奇金淋巴瘤 (HL) 是淋巴肿瘤。乙型肝炎病毒 (HBV)、丙型肝炎病毒 (HCV) 和人类免疫缺陷病毒 (HIV) 是可以在淋巴组织中增殖的病毒。这些病毒可能导致淋巴组织增生性疾病。本研究的目的是评估弥漫性大 B 细胞淋巴瘤 (DLBCL) 和 HL 患者中 HBV、HCV 和 HIV 的血清阳性率，比较这两个疾病组之间的关系并确定三种病毒之间的关系以及他们的特点。材料与方法：本研究为回顾性研究。2012 年 1 月 1 日至 2019 年 5 月 1 日期间在血液科和肝炎门诊部接受随访的患者被纳入研究。结果：在乙型肝炎表面抗原 (HBsAg)、乙型肝炎核心 (HBc) IgG 抗体、乙型肝炎 e 抗原 (HBeAg) 和抗 HBe 血清学阳性方面观察到疾病组之间的统计学显着相关性 (P = 0.004, P = 0.006、P = 0.041 和 P = 0.014，分别）。在抗 HCV 血清学阳性方面，疾病组之间也存在统计学上的显着关系（P = 0.029）。DLBCL 患者的 HBsAg、抗 HBc IgG、HBeAg、抗 Hbe 和 HCV 血清学阳性率高于 HL 患者。结论：这些发现表明肝炎病毒和DLBCL之间可能存在关系。在开始治疗之前评估这些患者的 HBV 和 HCV 感染被认为有利于启动抗病毒预防措施以防止血清反应阳性病例的再激活。此外，在 HCV 和 HBV 感染的随访中应注意淋巴瘤的发展。